company background image
ILMN logo

Illumina WBAG:ILMN Stock Report

Last Price

€124.10

Market Cap

€19.7b

7D

3.1%

1Y

-37.3%

Updated

26 Mar, 2024

Data

Company Financials +

ILMN Stock Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.

ILMN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Illumina, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Illumina
Historical stock prices
Current Share PriceUS$124.10
52 Week HighUS$215.40
52 Week LowUS$86.09
Beta1.19
1 Month Change0%
3 Month Change-1.87%
1 Year Change-37.32%
3 Year Change-63.77%
5 Year Change-56.14%
Change since IPO-20.75%

Recent News & Updates

Recent updates

Shareholder Returns

ILMNAT Life SciencesAT Market
7D3.1%3.6%0.9%
1Y-37.3%-3.8%6.9%

Return vs Industry: ILMN underperformed the Austrian Life Sciences industry which returned -5% over the past year.

Return vs Market: ILMN underperformed the Austrian Market which returned 7.4% over the past year.

Price Volatility

Is ILMN's price volatile compared to industry and market?
ILMN volatility
ILMN Average Weekly Movement4.6%
Life Sciences Industry Average Movement6.2%
Market Average Movement3.3%
10% most volatile stocks in AT Market5.0%
10% least volatile stocks in AT Market1.6%

Stable Share Price: ILMN has not had significant price volatility in the past 3 months.

Volatility Over Time: ILMN's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.

About the Company

FoundedEmployeesCEOWebsite
199810,615Jacob Thaysenhttps://www.illumina.com

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Illumina, Inc. Fundamentals Summary

How do Illumina's earnings and revenue compare to its market cap?
ILMN fundamental statistics
Market cap€19.67b
Earnings (TTM)-€1.07b
Revenue (TTM)€4.16b

4.7x

P/S Ratio

-18.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ILMN income statement (TTM)
RevenueUS$4.50b
Cost of RevenueUS$1.56b
Gross ProfitUS$2.94b
Other ExpensesUS$4.10b
Earnings-US$1.16b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-7.31
Gross Margin65.30%
Net Profit Margin-25.78%
Debt/Equity Ratio25.9%

How did ILMN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.